一个系统的审查和对成年人大动脉缩管理支架的元分析
Petroula Nana1, Konstantinos Spanos1,2, Alexandros Brodis3
1Vascular Surgery Department, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
概括
在成年人中,用于大动脉缩 (CoA) 的支架显示出高的技术成功率 (97%),可接受的手术内和30天死亡率. 中期随访显示,重新干预率很低,证明了这种内血管方法的安全性和有效性.
科学领域:
- 心血管外科心血管外科
- 干预心脏病学 干预心脏病学
- 医疗器械 医疗器械
背景情况:
- 大动脉缩 (CoA) 是一种先天性心脏缺陷,通常在成年时被诊断出来,呈现为先天性或复发性疾病.
- 之前的内血管治疗,如血管造形术,已经显示出高的并发症和重新干预率.
- 支架提供了一个潜在的更安全和更有效的内血管解决方案,用于成人CoA.
研究的目的:
- 系统地审查和分析成人大动脉缩 (CoA) 内血管支架的结果.
- 评估技术成功,再干预率和与CoA支架相关的死亡率.
- 将支架结果与其他内血管干预的历史数据进行比较.
主要方法:
- 在PubMed,EMBASE和CENTRAL数据库中进行了系统的文献搜索,截至2021年12月30日.
- 包括专注于使用支架治疗的原生或复发性CoA的成年患者的研究.
- 使用比例元分析来评估技术成功,手术内并发症,30天死亡率和中期重新干预率.
主要成果:
- 分析包括了27篇文章,其中包括705名成年患者 (65.7%为本地COA).
- 技术成功率高达97% (95% CI,0.96%-0.99%). 这是一个很好的方法.
- 术内并发症 (破裂,剖析) 和30天死亡率很低 (1-2%). 中期再干预率为8% (95% CI,0.05%-0.10%),其中95.5%通过血管内治疗.
结论:
- 针对成人大动脉缩 (CoA) 的内血管支架显示出高的技术成功率和可接受的安全性.
- 术内和30天死亡率较低,中期重新干预率可控.
- 支架是成人CoA的安全和有效的内血管选择,尽管对支架类型的进一步研究是有必要的.
相关概念视频
01:25Aortic Regurgitation III: Medical Management
26
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
26
01:26Aneurysm III: Interprofessional Care
12
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
12
01:26Mitral Stenosis III: Medical Management
14
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
14
01:26Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
11
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
11
01:26Angina IV: Management
11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11